Sanofi hiked Flublok price 12.5% last season by Eric Sagonowsky Wednesday, June 6, 2018 Sanofi raised the price of Flublok by 12.5% last year, its only increase above the U.S. National Health Expenditure growth rate.
Sanofi tweaks pricing policies, discloses 8.4% net price decline in 2017 by Eric Sagonowsky Friday, June 1, 2018 Sanofi's net prices fell 8.4% last year, the drugmaker reported in an update to its pricing policies.
Sanofi licenses cell-based vaccine technology in $155M deal by Angus Liu Monday, February 12, 2018 The licensing deal provides Sanofi Pasteur access to a cell culture technology for use in its universal influenza vaccine.
Dispute brewing over exit of Protein Sciences CEO by Eric Sagonowsky Thursday, January 4, 2018 Not long after its acquisition by Sanofi, Protein Sciences is bidding adieu to its former leader.
Egg allergies are no reason to pass on flu shots, guidelines say by Eric Sagonowsky Tuesday, December 19, 2017 Health experts presented flu vaccination guidelines stressing there's no difference in safety for shots given people allergic to eggs.
Sanofi finally nabs a deal with $650M biotech buy by Eric Sagonowsky Tuesday, July 11, 2017 Though not nearly on the scale of Sanofi's runs at Medivation or Actelion, the Protein Sciences buyout promises a boost for its flu vaccines lineup.
Astellas ditches Flublok collab after Japanese rebuff by Eric Sagonowsky Tuesday, January 17, 2017 Astellas pulled the plug on a cell culture flu vaccine partnership with UMN Pharma after Japanese regulators stiff-armed its application for approval.
UPDATED: Protein Sciences sets sights on quadrivalent flu vax market by Eric Sagonowsky Monday, October 17, 2016 Just a month after winning a big government contract for pandemic flu preparedness, Protein Sciences has notched an FDA approval for its next flu vaccine offering.
